Boston Scientific Corporation (NYSE:BSX) Stock Has Average Price Target of $70.19

Shares of Boston Scientific Corporation (NYSE:BSX) have been assigned an average rating of “Moderate Buy” from the thirty analysts that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, five have issued a hold recommendation and twenty-three have issued a buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $66.31.

Several equities analysts recently weighed in on BSX shares. Truist Financial lowered their target price on Boston Scientific from $62.00 to $57.00 and set a “buy” rating on the stock in a research report on Thursday, July 30th. Robert W. Baird set a $56.00 price objective on Boston Scientific in a research note on Thursday, July 30th. Raymond James Financial reaffirmed an “outperform” rating and set a $57.00 price objective on shares of Boston Scientific in a research report on Thursday, July 30th. Leerink Partners set a $60.00 price objective on Boston Scientific in a research note on Thursday, July 30th. Finally, Stifel Nicolaus set a $60.00 target price on shares of Boston Scientific in a report on Wednesday, July 29th.

Boston Scientific Price Performance

NYSE BSX opened at $42.19 on Wednesday. Boston Scientific has a 1-year low of $41.94 and a 1-year high of $105.65. The business’s fifty day moving average price is $46.81 and its 200-day moving average price is $51.11. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The stock has a market capitalization of $61.14 billion, a price-to-earnings ratio of 17.08, a PEG ratio of 1.02 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. The business had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company’s quarterly revenue was up 7.5% on a year-over-year basis. During the same period last year, the firm earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, equities analysts predict that Boston Scientific will post 3.25 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Michael Mahoney acquired 186,240 shares of Boston Scientific stock in a transaction dated Monday, August 3rd. The stock was purchased at an average cost of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the purchase, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. This trade represents a 13.27% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David Habiger acquired 2,100 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The shares were purchased at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the transaction, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 194,522 shares of company stock worth $9,385,210 over the last three months. 0.34% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Boston Scientific

A number of hedge funds have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in Boston Scientific in the 2nd quarter worth approximately $5,534,781,000. State Street Corp grew its holdings in Boston Scientific by 1.4% during the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after buying an additional 920,495 shares in the last quarter. Primecap Management Co. CA bought a new stake in shares of Boston Scientific during the second quarter valued at approximately $2,156,233,000. Capital World Investors lifted its holdings in shares of Boston Scientific by 1.9% in the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock worth $2,588,953,000 after buying an additional 502,627 shares in the last quarter. Finally, Jupiter Topco LLC purchased a new position in shares of Boston Scientific in the second quarter worth $803,357,000. Institutional investors own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company’s portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.